Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera. Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: Health Care:Physician Practices headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.

Read full article on